Petauri
Overview
Pharmaceutical commercialization platform formed in 2023 by Oak Hill Capital and Dan Renick, whose units Petauri Advisors, Petauri Evidence, and Petauri MAx deliver pricing and market access strategy, HEOR/value evidence, and payer engagement.
Notable
Built via acquisitions including The Kinetix Group, Formulary Insights, Artia Solutions, Mtech Access, and Delta Hat; Oak Hill committed $250M+ of equity.
Key services
- Pricing & market access strategy
- Value demonstration & HEOR
- Payer research (Formulary Insights)
- Market access communications
Subcategories
Verified Reviews
No verified reviews yet — are you a customer of Petauri? Share your experience in a short, confidential interview.
Share your experience